Why a universal antiretroviral regimen?

Affiliations

¹ aDivisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA bHIV-Base, London, UK cWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.

Editorial

Charles W Flexner et al. Curr Opin HIV AIDS. 2017 Jul.

. 2017 Jul;12(4):315-317.

doi: 10.1097/COH.0000000000000390.

¹ aDivisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA bHIV-Base, London, UK cWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.

No abstract available

References

1. UNAIDS. [Accessed April 26, 2017];Global AIDS Update 2016. http://www.who.int/hiv/pub/arv/global-AIDS-update-2016_en.pdf.
1. Cohen MS, Chen YQ, McCauley M, et al. HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl JMed. 2016;375:830–839. - PMC - PubMed
1. Daniel Willem, Venter Francois, Clayden Polly, Serenata Celicia. The ADVANCE Study: A Groundbreaking Trial to Evaluate a Candidate Universal Antiretroviral Regimen. Curr Opin HIV AIDS. 2017 - PMC - PubMed
1. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravircontaining combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30:2831–2834. - PubMed
1. Wijting I, Rokx C, Wit F, et al. Integrase inhibitors are an independent risk factor for IRIS: an ATHENA cohort study. CROI 2017; 13–16 February 2017; Seattle. Poster abstract 731; [Accessed 26 April 2017]. Available from: http://www.croiconference.org/sessions/integrase-inhibitors-are-independ....